• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Questions for Medicare in Meningitis Outbreak

Article

Medicare is coming under scrutiny in the meningitis outbreak that has rekindled doubts about the safety of the nation's drug supply.

The giant health insurance program for seniors long ago flagged compounded drugs produced for the mass market without oversight from the Food and Drug Administration as safety risks. In 2007, Medicare revoked coverage of compounded inhaler drugs for lung disease.

Read the full story: http:/bit.ly/OQziq3

Source: The Associated Press

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Dr Johnie Rose
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Dr Andrew S. Oseran
o Richard Hughes IV, JD, MPH, Epstein Becker Green
Dr Andrew S. Oseran
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.